EcoDrugPlus

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSATEG00000017802
Gene Symbol: EPAS1B
2 Cross references
211 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSATEG00000025157
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Ba

Ensembl ID : ENSATEG00000003790
Gene Symbol: EDNRBA
2 Cross references
178 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSATEG00000020501
Gene Symbol: EDNRA
1 Cross references
201 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSATEG00000012561
Gene Symbol: EDNRAA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Bb

Ensembl ID : ENSATEG00000013765
Gene Symbol: EDNRBB
2 Cross references
200 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSATEG00000021762
Gene Symbol: EZH2
2 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSATEG00000003981
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSATEG00000010108
Gene Symbol: LOC113159000
2 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSATEG00000014468
Gene Symbol: LOC113161959
2 Cross references
207 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSATEG00000019808
Gene Symbol: ERBB2
2 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3b

Ensembl ID : ENSATEG00000022245
Gene Symbol: ERBB3B
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).